MedTrace Logo

Post-Authorization Study Evaluating Safety Of Tigecycline

NCT00827541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2012-02-01

Study results available
· View outcomes & findings →

Summary

This is a study to evaluate the safety of tigecycline in patients with complicated intra-abdominal infections (cIAI) and complicated skin and soft tissue infections (cSSTI) under real practice in the usual hospital setting and patients' conditions, in order to assess the "real incidence" of adverse events related with tigecycline in these patients.

Conditions

  • Intra-Abdominal Infections
  • Skin Disease, Infectious
  • Soft Tissues Infections

Interventions

DRUG

Tigecycline

Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827541 on ClinicalTrials.gov